-
NRX Pharmaceuticals NASDAQ:NRXP NeuroRx draws upon more than 100 years of collective drug development experience from senior executives of AstraZeneca, Eli Lilly, Novartis, Pfizer, and PPD. In addition to its work on Aviptadil, NeuroRx has been awarded Breakthrough Therapy Designation and a Special Protocol Agreement to develop NRX-101 in suicidal bipolar depression and is currently in Phase 3 trials. Its executive team is led by Prof. Jonathan C. Javitt, MD, MPH, who has served as a health advisor to four Presidential administrations and worked on paradigm-changing drug development projects for Merck, Allergan, Pharmacia, Pfizer, Novartis, and Mannkind, together with Robert Besthof, MIM, who served as the Global Vice President (Commercial) for Pfizer's Neuroscience and Pain Division. NeuroRx recently announced a plan to complete a business combination with Big Rock Partners Acquisition Corp ('BRPA'), and intends to apply for listing on the NASDAQ under the proposed symbol 'NRXP'.
Location: 2645 N Federal Hwy Ste 230, Florida, 33483-6111, US | Website: www.nrxpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
18.64M
Cash
1.898M
Avg Qtr Burn
-3.497M
Short % of Float
8.60%
Insider Ownership
23.56%
Institutional Own.
6.05%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HTX-100 (ketamine) Details Acute Suicidal Ideation and Behavior, Bipolar depression | NDA Submission | |
NRX-100 (IV ketamine) Details Suicidal Depression | NDA Submission | |
NRX-101 Details Treatment Resistant Depression, Bipolar depression | NDA Submission | |
NRX-101 Details Chronic pain | Phase 2 Data readout | |
NRX-101 Details Post-traumatic stress disorder | Phase 2 Initiation | |
BRILIFE Details COVID-19 | Failed Discontinued | |
Failed Discontinued |